Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Clinical trial NCT05640830 · RECRUITING

Trial details

NCT number: NCT05640830
Sponsor: Kangbuk Samsung Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Advanced Gastric Cancer

Start date: 2023-01-01
Primary completion: 2025-12-31
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.